The Ridiculousness of Ambarella


Targets:  12 month price -$60 / 18 month – $40


It seems like yesterday that Wall Street was frothing at the mouth over 3D printing stocks.  These high flyers were not valued based on their financials but rather as a beneficiary of being anointed as “the new new”.  Citron Research was critical of the space and published pieces on 3 of these bubble-levitated 3D printing stocks.  It is 18 months later and most of them languish 80% off their highs.

So Wall Street has gone searching for another “new new” in the technology sector and has found one in Ambarella (NASDAQ:AMBA), whose parabolic frenzy has now launched it into a realm that can’t possibly be supported by reality.  Citron points out how how far this niche chip designer's stock has separated from reality. 


For an unpretentious episode of investing "reality TV", click here.




Citron Chimes on Lumber Liquidators — Before You Short Down Here — Step Back and Read


Obviously Lumber Liquidators (NYSE:LL) has an image problem, but Citron believes the selloff is largely overdone here.  

The stock is off 60% from when its CEO first warned that an unfavorable 60 Minutes story was coming, but the reality is that the actions and advice of the California Air Resources Board ought to be considered and heeded by all investors.

So before piling on this short at these levels, perhaps a step back and rational reassessment would be a good idea. 

For the Full Commentary, Click Here


AXDX Big Lie Exposed by SEC — $1.00 Target within 18 Months


It is well known that Accelerate Diagnostics (NASDAQ:AXDX) is a controversial stock.  Here are the main reasons:

*   11 years of unfulfilled promises about the same product

*   No viable commercial product on the immediate horizon

*   Scant R&D

*   Technology rejected by two major pharma companies, who each had exclusive rights to AXDX's platform for months — and then walked away

*   Not a single independent scientific publication on its technology — despite over 30 papers authored by employees, and individuals compensated by the company

*   A competitive landscape increasingly crowded with high-credibility and well funded competitors, each aggressively bringing new technologies to market — many already FDA approved and/or Europe CE approval

Citron won't rehash previously published stories about his company's suspect past, but rather focus on the heart of what is new, unreported and publicly sourced.  We'll step you through the extraordinary sequence in which the SEC at its finest, forces the company to fess up and abandon its 10+ year misleading overreach of a story about rapid diagnostics using direct from patient blood samples.

This company's claim to innnovative medical diagnostic technology has been exposed by its own filings.  It is careening toward irrelevance without a viable product. 


For the Story You Won't Read Anywhere Else, Click Here

(As always, Citron recommends you download the PDF, then right-click to follow the links)